Composite Conjugated Polymer/Fullerene Nanoparticles as Sensitizers in Photodynamic Therapy for Cancer

被引：6
作者：
Doshi M. [1 ]
Treglown K. [1 ]
Copik A. [2 ]
Gesquiere A.J. [1 ]
机构：
[1] NanoScience Technology Center, Department of Chemistry and CREOL, The College of Optics and Photonics, University of Central Florida, 12424 Research Parkway Suite 400, Orlando, 32826, FL
[2] Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Boulevard, Orlando, 32827, FL
来源：
BioNanoScience | 2014年 / 4卷 / 01期
基金：
美国国家科学基金会;
关键词：
Apoptosis; Conducting polymer; Oxidative stress; Reactive oxygen species; ROS; Tumor;
D O I：
10.1007/s12668-013-0114-5
中图分类号：
学科分类号：
摘要：
The fabrication and study of composite conjugated polymer nanoparticles doped with fullerene for application in photodynamic therapy (PDT) is reported. The nanoparticles are not intrinsically cytotoxic and show specificity towards cancer cells without surface modification. The high absorption cross-section and efficient charge transfer from conjugated polymer to fullerene in the composite nanoparticles results in only moderate light levels being necessary for PDT. The PDT scheme was tested in vitro for MDA-MB-231 (human breast cancer), A549 (human lung cancer), and OVCAR3 (human ovarian cancer) cell lines. While the treatment was observed to be only marginally effective for the MDA-MB-231 cell line, 60 % and complete cell death was observed for the A549 and OVCAR3 cell lines, respectively. Differences in PDT efficiency are attributed to the difference in nanoparticle uptake between these cell lines, and is potentially related to differences in metabolic rate. Through live/dead cell staining apoptotic cell death was observed for OVCAR3. This is a promising finding for potential development of treatment for ovarian cancer by the PDT scheme discussed herein. © 2013, Springer Science+Business Media New York.
引用
收藏
页码：15 / 26
页数：11
相关论文
共 76 条
[1]  
Kumar A., Cascarini L., McCaul J.A., Kerawala C.J., Coombes D., Godden D., Et al., How should we manage oral leukoplakia?, British Journal of Oral and Maxillofacial Surgery, 51, 5, pp. 377-383, (2013)
[2]  
Milovanovic J., Djukic V., Milovanovic A., Jotic A., Banko B., Jesic S., Et al., Clinical outcome of early glottic carcinoma in Serbia, Auris, Nasus, Larynx, 40, 4, pp. 394-399, (2013)
[3]  
Moore E.J., Hinni M.L., Critical review: Transoral laser microsurgery and robotic-assisted surgery for oropharynx cancer including human papillomavirus-related cancer, International Journal of Radiation Oncology, Biology, and Physics, 85, 5, pp. 1163-1167, (2013)
[4]  
No D., Osterberg E.C., Otto B., Naftali I., Choi B., Evaluation of continence following 532 nm laser prostatectomy for patients previously treated with radiation therapy or brachytherapy, Lasers in Surgery and Medicine, 45, 6, pp. 358-361, (2013)
[5]  
Rosch T., Progress in endoscopy: areas of current interest and topics to watch out for, Endoscopy, 44, 12, pp. 1148-1157, (2012)
[6]  
Kalbasi A., June C.H., Haas N., Vapiwala N., Radiation and immunotherapy: a synergistic combination, Journal of Clinical Investigation, 123, 7, pp. 2756-2763, (2013)
[7]  
Suneja G., Poorvu P.D., Hill-Kayser C., Lustig R.A., Acute toxicity of proton beam radiation for pediatric central nervous system malignancies, Pediatric Blood & Cancer, 60, 9, pp. 1431-1436, (2013)
[8]  
Dent S., Oyan B., Honig A., Mano M., Howell S., HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials, Cancer Treatment Reviews, 39, 6, pp. 622-631, (2013)
[9]  
Heinemann V., Douillard J.Y., Ducreux M., Peeters M., Targeted therapy in metastatic colorectal cancer—an example of personalised medicine in action, Cancer Treatment Reviews, 39, 6, pp. 592-601, (2013)
[10]  
Verbrugghe M., Verhaeghe S., Lauwaert K., Beeckman D., Van Hecke A., Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review, Cancer Treatment Reviews, 39, 6, pp. 610-621, (2013)
12345678